Ebola hemorrhagic fever is a severe, often-fatal disease in humans and nonhuman primates (monkeys, gorillas, and chimpanzees) that has appeared sporadically since its initial recognition in 1976. The disease is caused by infection with Ebola virus, named after a river in the Democratic Republic of the Congo (formerly Zaire) in Africa, where it was first recognized. The virus is one of two mem bers of a family of RNA viruses called the Filoviridae. There are four identified subtypes of Ebola virus. Three of the four have caused disease in humans: Ebola-Zaire, Ebola-Sudan, and Ebola-Ivory Coast. The fourth, Ebola-Reston, has caused disease in nonhuman primates, but not in humans.
The outbreak of the deadly Ebola in the Democratic Republic of Congo has spread outside the province of North Kivu according to a statement made by the country’s health ministry yesterday. With this the viral infection has reached an active conflict zone and this may mean that it could spread wider now.
The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.
Ebola – from a small village in Guinea, the deadly virus took hold of West Africa in 2014, and to date has taken the lives of over 10,000 people. The virus threatens to destabilize world health efforts and has induced global fear, with citizens from far away nations concerned about the “what ifs?” of Ebola landing on their doorsteps...
People tried to avoid a healthcare situation and in doing so, they propagated it through the community because instead of being in isolation they remained around the family group and relied on usual cultural health remedies...
Interim findings from a clinical trial (PREVAIL) in which two experimental Ebola vaccines were given to more than 600 people in Liberia indicate that the vaccines are safe for use in humans. Based on these positive results, the vaccines may continue into the next stage of clinical evaluation; a phase 3 trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
There are hundreds of other antibodies against Ebola that we are in the process of imaging using the electron microscope. We are looking for new sites of vulnerability as well as subtle differences in the way the known sites are attacked. In particular we are looking for antibodies that the virus is unlikely to escape from when it mutates.
Leading medical organisations are due to speak at the first ever Medical Support Operations Conference, a three-day event providing a unique opportunity to network with industry leaders, NGOs and military end users’ such as Humanity First and the European External Action Service.
GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine.
A case report, published in The Lancet today, describes the successful treatment of Ebola using a new drug under clinical development for vascular leakage (FX06, a fibrin-derived peptide).
An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug.
Médecins Sans Frontières/Doctors without Borders (MSF) have announced that three trials of Ebola therapies will begin in West Africa this December.
Cleaver Scientific reports that its horizontal electrophoresis equipment is being used on the frontline of the UK fight against Ebola.
The Centers for Disease Control and Prevention has announced that any person flying into the USA from Liberia, Sierra Leone or Guinea will soon have to undergo daily Ebola monitoring for several weeks after their arrival.
Current methods for diagnosing infectious diseases are based on the 150-year-old culture method, where physicians collect a sample of a patient’s tissue, such as blood, mucus or urine, and transfer it onto media bottle to allow the pathogens to grow.
The recent occurrences of Ebola cases outside Africa has led to fears of a global epidemic. The US Centers for Disease Control and Prevention (CDC) has estimated that the number of infections could rise to up to 1.4 million people by early next year without a massive global intervention to contain the virus.